SCHEMBL15420889

SCHEMBL15420889

O=C(c1ccc(OCc2ccccc2)cc1)N1CCCCC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.76
RAB9A P51151 5/20 0.76
ALDH1A1 P00352 5/20 0.76
MAPT P10636 2/20 0.76
CASP3 P42574 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
SLC6A7 Q99884 1/20 0.69
SMN1; SMN2 Q16637 3/20 0.65
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
HPGD P15428 6/20 0.65
EGFR P00533 3/20 0.64
ATM Q13315 1/20 0.64
TP53 P04637 2/20 0.63
LMNA P02545 1/20 0.63
HTT P42858 1/20 0.63
RECQL P46063 1/20 0.63
KDM4E B2RXH2 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1977856 0.96 SLC6A7 (0.70) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL11081153 0.87 SLC6A7 (0.61) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL5851806 0.86 SLC6A7 (0.66) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL19313610 0.85 ALDH1A1 (0.60) NPC1RAB9AALDH1A1MAPTCASP3
Ethylene SCHEMBL8377795 0.84 SLC6A7 (0.63) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL19313641 0.83 ALDH1A1 (0.61) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL1169664 0.83 HRH3 (0.61) NPC1RAB9AALDH1A1MAPTSLC6A7
SCHEMBL5650813 0.83 SMN1; SMN2 (0.67) NPC1RAB9AALDH1A1CASP3SENP8
SCHEMBL20748143 0.83 LMNA (0.72) NPC1RAB9AALDH1A1MAPTCASP3
SCHEMBL20748051 0.83 LMNA (0.72) NPC1RAB9AALDH1A1MAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 NPC1 2770/4885RAB9A 3305/4885ALDH1A1 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.